Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine, in patients who do not develop any rash, or develop only grade 1 rash, within 4 weeks of start of treatment with gemcitabine + erlotinib, if overall survival can be improved by increasing the dose of erlotinib compared to patients who continue on 100 mg erlotinib.
Critère d'inclusion
- Pancreatic cancer